Dermatologic care for lesbian, gay, bisexual, and transgender persons : Epidemiology, screening, and disease prevention - 11/02/19
Abstract |
Lesbian, gay, bisexual, and transgender (LGBT) persons face important health issues relevant to dermatologists. Men who have sex with men (MSM) are at higher risk of certain infectious diseases, including HIV, syphilis and other sexually transmitted diseases (STDs), methicillin-resistant Staphylococcus aureus infections, and invasive meningococcal disease, and might be at higher risk of non-infectious conditions, including skin cancer. Recommendations for preventive health care, including screening for HIV and other STDs, sexual health-related vaccinations, and HIV pre-exposure prophylaxis, differ for MSM compared with non-MSM. Women who have sex with women experience disparities in STDs, including chlamydia and HPV. Transgender patients have unique, and often unmet, dermatologic needs during gender transition (also called gender affirmation), related to hormonal therapy and gender-affirming surgery. Familiarity with LGBT health issues and disease-prevention guidelines can enable dermatologists to provide medically appropriate and culturally competent care to LGBT persons.
Le texte complet de cet article est disponible en PDF.Key words : bisexual, cross-sex hormone, dermal fillers, dermatology, gay, gender affirmation, HIV, indoor tanning, lesbian, LGBT, sexually transmitted diseases, sexual minority, skin cancers, transgender
Abbreviations used : CDC, HHV-8, HPV, HSV-2, LGBT, MRSA, MSM, nPEP, PrEP, STD, USPSTF, WSW
Plan
Supported in part by the Dermatology Foundation and the National Center for Advancing Translational Sciences of the National Institutes of Health under grant numbers UL1TR002378 and KL2TR002381 (Dr Yeung). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. |
|
Dr Yeung received honorarium from InVentiv Health. Dr Katz was a stockholder in Prevention Health Labs and Arrowhead Pharmaceuticals. All other authors had no potential conflicts of interest to disclose. |
|
Date of release: March 2019 |
|
Expiration date: March 2022 |
Vol 80 - N° 3
P. 591-602 - mars 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?